Table 5.
Combination OV and adoptive cell clinical trials for cancers
| Biological agent | Combination | Indication | Status | Sponsor | Trial ID |
|---|---|---|---|---|---|
| TILT-123 (adenovirus coding TNFα and IL2) | adoptive cell therapy with TILs | metastatic melanoma | recruiting, phase I | TILT Biotherapeutics | NCT04217473 |
| CAdVEC (binary oncolytic adenovirus) | HER2-specific CAR-T cells | advanced solid tumors | recruiting, phase I | Baylor College of Medicine | NCT03740256 |
| VCN-01 (oncolytic adenovirus expressing hyaluronidase) | mesothelin-specific CAR-T cells | pancreatic cancer, serous ovarian cancer | recruiting, phase I | University of Pennsylvania | NCT05057715 |
| OVV-01 (oncolytic vaccinia virus) | trained immunity NK cells IBR900 | advanced solid tumors including lymphoma | terminated | Beijing Boren Hospital | NCT05271279 |